The global contraceptive drugs market size reached USD 16.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.64% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 16.6 Billion |
Market Forecast in 2033
|
USD 25.5 Billion |
Market Growth Rate 2025-2033 | 4.64% |
Contraceptive drugs refer to birth control medications that are used to prevent pregnancy and control the birth rate. They are synthetically formulated using two female hormones, namely estrogen and progestin, which prevent ovulation. These hormones also thicken cervical mucus or alter the womb lining to prohibit the entrance of sperm into the cervix for fertilization and implantation. Contraceptive drugs assist in lowering the risks of acne, bone thinning, ovarian cancer, infections in the fallopian tubes and uterus, and premenstrual syndrome (PMS). As a result, they are administered by healthcare practitioners to inhibit unwanted pregnancy amongst women of childbearing age. At present, they are mainly available in oral, injectable, and topical formulations.
One of the key factors driving the global contraceptive drugs market is the rising consumer consciousness regarding family planning, the increasing population, and the rising instances of unintended pregnancies. In line with this, the shifting inclination of healthcare practitioners toward modern contraceptive methods over conventional procedures, owing to their multiple benefits, including optimal safety, and better clinical outcomes, are acting as another growth-inducing factor. Additionally, the frequent approvals of novel medications by several regulatory bodies, such as the food and drug administration (FDA), are supporting the market growth. Moreover, the advent of gelatin capsules and non-hormonal vaginal gels that create an inhospitable environment for sperm to sustain by maintaining vagina pH levels is impelling the market growth. Apart from this, continuous research and development (R&D) activities and the favorable initiatives undertaken by non-governmental organizations (NGOs) and health agencies to sensitize consumers about contraception techniques, women’s health, and sexual wellness are positively augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive drugs market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, age group and distribution channel.
Breakup by Product:
Breakup by Age Group:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and Viatris Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Age Group, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and Viatris Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global contraceptive drugs market was valued at USD 16.6 Billion in 2024.
We expect the global contraceptive drugs market to exhibit a CAGR of 4.64% during 2025-2033.
The rising consumer consciousness towards family planning, along with the increasing demand for contraceptive drugs among healthcare practitioners to inhibit unwanted pregnancies, is primarily driving the global contraceptive drugs market.
The sudden outbreak of the COVID-19 pandemic had led to the growing R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for contraceptive drugs market.
Based on the product, the global contraceptive drugs market can be divided into oral contraceptive pills, injectable contraceptives, and topical contraceptives. Currently, oral contraceptive pills account for the largest market share.
Based on the age group, the global contraceptive drugs market has been segregated into 15–24 years, 25–34 years, 35–44 years, and above 44 years. Among these, 15-24 years currently hold the majority of the total market share.
Based on the distribution channel, the global contraceptive drugs market can be bifurcated into retail pharmacy, hospital pharmacy, clinics, online channel, public channel and NGOs, and others. Currently, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global contraceptive drugs market include AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.